Back to Results
First PageMeta Content
Pharmacology / Dipeptidyl peptidase-4 inhibitors / Amides / Dow Jones Industrial Average / Merck & Co. / Readington / New Jersey / Sitagliptin / Metformin / Diabetes mellitus / Medicine / Anti-diabetic drugs / Chemistry


*JANUVIA™ is the proposed trademark for MK-431 (sitagliptin phosphate)
Add to Reading List

Document Date: 2014-10-08 00:16:31

Open Document

File Size: 167,90 KB

Share Result on Facebook

Company

Merck & Co. Inc. / MERCK / Merck Sharp & Dohme Corp. / Statistics Canada / /

Country

United States / Canada / /

Currency

cent / /

/

IndustryTerm

animal health products / overall healthcare costs / manufacturing difficulties / sitagliptin products / health solutions / pharmaceutical industry regulation / healthcare / healthcare system costs / /

MedicalCondition

cardiovascular disease / prediabetes / diabetes / prescription diabetes / complex chronic condition / renal disease / end-stage renal disease / hypoglycemia / /

MedicalTreatment

biologic therapies / amputations / /

Organization

Canadian Diabetes Association / Merck Customer Information Centre / Public Health Agency of Canada / Pharmaceutical Services Division / Securities and Exchange Commission / British Columbia Medical Beneficiary and Pharmaceutical Services Division / /

Person

Justin Holko / Annick Robinson / /

/

Position

general economic factors / Private / global healthcare leader / /

Product

JANUMET / JANUVIA / metformin hydrochloride / /

ProvinceOrState

British Columbia / /

URL

www.sec.gov / http /

SocialTag